|
Keynote Speakers
Prof. Stephen C. Harrison, Harvard University
Dr. Sandra Jacobs, Novartis (Basel)
and speakers from: Vertex, Amgen, Wyeth, Pfizer,
Novartis, Transform
Final Program
|
8:00-9:00 |
An Accelrys Breakfast |
|
|
9:00-9:15 |
Introductory remarks |
|
|
9:15-10:15 |
Keynote Speaker: "Viral fusion
proteins as targets for viral entry
inhibitors" |
Professor Stephen C Harrison -
Harvard University |
|
10:15-10:45 |
"Crystal structures of MEK1 and MEK2: Novel
mode of kinase inhibition and implications in drug
design" |
Huifen Chen - Pfizer (Ann Arbor,
Michigan) |
|
10:45-11:00 |
An IBM coffee break |
|
|
11:00-11:30 |
"Classification of kinase X-ray structures
reveals discrete conformations with distinct
ligand binding pockets" |
Brian Hare - Vertex |
|
11:30-12:00 |
"Crystallography and Drug Discovery of VEGF
Receptor Kinase Inhibitors." |
Doug Whittington
- Amgen |
|
12:00-1:00 |
A Rigaku Lunch - "Improving your
Pipeline"
|
Joseph Ferrara - Rigaku (12:30 - 1:00) |
|
1:00-2:00 |
Keynote Speaker: "What we did to
support drug discovery for the Gleevec- follow-up
project" |
Dr Sandra Jacobs - Novartis (Basel) |
|
2:00-2:30 |
"The practical challenges of designing
Kinase drugs; a modeling perspective" |
Ian
McFadyen - Transform Pharmaceuticals |
|
2:30-3:00 |
"The biology of PKCs" |
Divya
Chaudry - Wyeth |
|
3:00-3:30 |
A GENEWIZ Coffee break |
|
|
3:30-4:00 |
"Baculovirus expression of protein kinases:
Lessons learnt" |
Ian Hunt - Novartis |
|
4:00-4:30 |
"TBD" |
Ernst ter Haar - Vertex |
|
5:00-7:00 |
A Fluidigm Mixer |
|
Sponsors
|
